Pregabalin Peripheral Neuropathic Pain Study

Summary

To evaluate the efficacy of pregabalin, using a flexible, optimized dose schedule with dose adjustment based on Daily Pain Rating Scale (DPRS), compared to placebo in subjects with peripheral neuropathic pain.

Timeline

Start

2005-12

Primary completion

2007-12

Completion

2007-12

Outcome

Met primary endpoint

registry analysis (unspecified test); Pregabalin vs Placebo; p = 0.049; Mean Difference (Final Values) -0.50 (95% CI -1.00 to -0.00); NCT00141219 ↗

Drugs

Indications